Cargando…

Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST

Background. More than 50% of operable GEA relapse after curative-intent resection. We aimed at externally validating a nomogram to enable a more accurate estimate of individualized risk in resected GEA. Methods. Medical records of a training cohort (TC) and a validation cohort (VC) of patients under...

Descripción completa

Detalles Bibliográficos
Autores principales: Salati, Massimiliano, De Ruvo, Nicola, Giglio, Mariano Cesare, Sorrentino, Lorena, Esposito, Giuseppe, Fenocchi, Sara, Cucciarrè, Giovanni, Serra, Francesco, Rossi, Elena Giulia, Vittimberga, Giovanni, Radi, Giorgia, Solaini, Leonardo, Morgagni, Paolo, Grizzi, Giulia, Ratti, Margherita, Gelsomino, Fabio, Spallanzani, Andrea, Ghidini, Michele, Ercolani, Giorgio, Dominici, Massimo, Gelmini, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500991/
https://www.ncbi.nlm.nih.gov/pubmed/36143086
http://dx.doi.org/10.3390/jcm11185439
_version_ 1784795360277823488
author Salati, Massimiliano
De Ruvo, Nicola
Giglio, Mariano Cesare
Sorrentino, Lorena
Esposito, Giuseppe
Fenocchi, Sara
Cucciarrè, Giovanni
Serra, Francesco
Rossi, Elena Giulia
Vittimberga, Giovanni
Radi, Giorgia
Solaini, Leonardo
Morgagni, Paolo
Grizzi, Giulia
Ratti, Margherita
Gelsomino, Fabio
Spallanzani, Andrea
Ghidini, Michele
Ercolani, Giorgio
Dominici, Massimo
Gelmini, Roberta
author_facet Salati, Massimiliano
De Ruvo, Nicola
Giglio, Mariano Cesare
Sorrentino, Lorena
Esposito, Giuseppe
Fenocchi, Sara
Cucciarrè, Giovanni
Serra, Francesco
Rossi, Elena Giulia
Vittimberga, Giovanni
Radi, Giorgia
Solaini, Leonardo
Morgagni, Paolo
Grizzi, Giulia
Ratti, Margherita
Gelsomino, Fabio
Spallanzani, Andrea
Ghidini, Michele
Ercolani, Giorgio
Dominici, Massimo
Gelmini, Roberta
author_sort Salati, Massimiliano
collection PubMed
description Background. More than 50% of operable GEA relapse after curative-intent resection. We aimed at externally validating a nomogram to enable a more accurate estimate of individualized risk in resected GEA. Methods. Medical records of a training cohort (TC) and a validation cohort (VC) of patients undergoing radical surgery for c/uT2-T4 and/or node-positive GEA were retrieved, and potentially interesting variables were collected. Cox proportional hazards in univariate and multivariate regressions were used to assess the effects of the prognostic factors on OS. A graphical nomogram was constructed using R software’s package Regression Modeling Strategies (ver. 5.0-1). The performance of the prognostic model was evaluated and validated. Results. The TC and VC consisted of 185 and 151 patients. ECOG:PS > 0 (p < 0.001), angioinvasion (p < 0.001), log (Neutrophil/Lymphocyte ratio) (p < 0.001), and nodal status (p = 0.016) were independent prognostic values in the TC. They were used for the construction of a nomogram estimating 3- and 5-year OS. The discriminatory ability of the model was evaluated with the c-Harrell index. A 3-tier scoring system was developed through a linear predictor grouped by 25 and 75 percentiles, strengthening the model’s good discrimination (p < 0.001). A calibration plot demonstrated a concordance between the predicted and actual survival in the TC and VC. A decision curve analysis was plotted that depicted the nomogram’s clinical utility. Conclusions. We externally validated a prognostic nomogram to predict OS in a joint independent cohort of resectable GEA; the NOMOGAST could represent a valuable tool in assisting decision-making. This tool incorporates readily available and inexpensive patient and disease characteristics as well as immune-inflammatory determinants. It is accurate, generalizable, and clinically effectivex.
format Online
Article
Text
id pubmed-9500991
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95009912022-09-24 Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST Salati, Massimiliano De Ruvo, Nicola Giglio, Mariano Cesare Sorrentino, Lorena Esposito, Giuseppe Fenocchi, Sara Cucciarrè, Giovanni Serra, Francesco Rossi, Elena Giulia Vittimberga, Giovanni Radi, Giorgia Solaini, Leonardo Morgagni, Paolo Grizzi, Giulia Ratti, Margherita Gelsomino, Fabio Spallanzani, Andrea Ghidini, Michele Ercolani, Giorgio Dominici, Massimo Gelmini, Roberta J Clin Med Article Background. More than 50% of operable GEA relapse after curative-intent resection. We aimed at externally validating a nomogram to enable a more accurate estimate of individualized risk in resected GEA. Methods. Medical records of a training cohort (TC) and a validation cohort (VC) of patients undergoing radical surgery for c/uT2-T4 and/or node-positive GEA were retrieved, and potentially interesting variables were collected. Cox proportional hazards in univariate and multivariate regressions were used to assess the effects of the prognostic factors on OS. A graphical nomogram was constructed using R software’s package Regression Modeling Strategies (ver. 5.0-1). The performance of the prognostic model was evaluated and validated. Results. The TC and VC consisted of 185 and 151 patients. ECOG:PS > 0 (p < 0.001), angioinvasion (p < 0.001), log (Neutrophil/Lymphocyte ratio) (p < 0.001), and nodal status (p = 0.016) were independent prognostic values in the TC. They were used for the construction of a nomogram estimating 3- and 5-year OS. The discriminatory ability of the model was evaluated with the c-Harrell index. A 3-tier scoring system was developed through a linear predictor grouped by 25 and 75 percentiles, strengthening the model’s good discrimination (p < 0.001). A calibration plot demonstrated a concordance between the predicted and actual survival in the TC and VC. A decision curve analysis was plotted that depicted the nomogram’s clinical utility. Conclusions. We externally validated a prognostic nomogram to predict OS in a joint independent cohort of resectable GEA; the NOMOGAST could represent a valuable tool in assisting decision-making. This tool incorporates readily available and inexpensive patient and disease characteristics as well as immune-inflammatory determinants. It is accurate, generalizable, and clinically effectivex. MDPI 2022-09-16 /pmc/articles/PMC9500991/ /pubmed/36143086 http://dx.doi.org/10.3390/jcm11185439 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Salati, Massimiliano
De Ruvo, Nicola
Giglio, Mariano Cesare
Sorrentino, Lorena
Esposito, Giuseppe
Fenocchi, Sara
Cucciarrè, Giovanni
Serra, Francesco
Rossi, Elena Giulia
Vittimberga, Giovanni
Radi, Giorgia
Solaini, Leonardo
Morgagni, Paolo
Grizzi, Giulia
Ratti, Margherita
Gelsomino, Fabio
Spallanzani, Andrea
Ghidini, Michele
Ercolani, Giorgio
Dominici, Massimo
Gelmini, Roberta
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
title Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
title_full Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
title_fullStr Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
title_full_unstemmed Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
title_short Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
title_sort development and multicenter validation of a novel immune-inflammation-based nomogram to predict survival in western resectable gastric and gastroesophageal junction adenocarcinoma (gea): the nomogast
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500991/
https://www.ncbi.nlm.nih.gov/pubmed/36143086
http://dx.doi.org/10.3390/jcm11185439
work_keys_str_mv AT salatimassimiliano developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT deruvonicola developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT gigliomarianocesare developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT sorrentinolorena developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT espositogiuseppe developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT fenocchisara developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT cucciarregiovanni developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT serrafrancesco developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT rossielenagiulia developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT vittimbergagiovanni developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT radigiorgia developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT solainileonardo developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT morgagnipaolo developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT grizzigiulia developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT rattimargherita developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT gelsominofabio developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT spallanzaniandrea developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT ghidinimichele developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT ercolanigiorgio developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT dominicimassimo developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast
AT gelminiroberta developmentandmulticentervalidationofanovelimmuneinflammationbasednomogramtopredictsurvivalinwesternresectablegastricandgastroesophagealjunctionadenocarcinomageathenomogast